ArticleRSC advances2026
Europium nanoparticle-based lateral flow assay for rapid detection of herpes simplex virus 2-specific antibodies in serum: a preliminary evaluation.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Herpes simplex virus type 2 (HSV-2) is a widely prevalent human pathogen responsible for the majority of genital herpes infections. Type-specific serological screening is a valuable approach for identifying asymptomatic individuals who may unknowingly transmit HSV to sexual partners and neonates, and can inform prevention, treatment, and vaccination strategies aimed at reducing transmission. Here, we describe the development and preliminary evaluation of a Europium nanoparticle-based lateral flow assay (EuNP-LFA) for rapid detection of HSV-2-specific immunoglobulin G (IgG) antibodies in human serum within 10 minutes. Preliminary performance evaluation using a commercially available anti-herpes mixed-titer performance panel demonstrated 90% sensitivity and 90.9% specificity relative to the FDA-cleared HerpeSelect™ HSV-2 ELISA reference classification. Receiver operating characteristic analysis yielded an area under the curve of 0.918 (95% CI: 0.688-0.983), indicating good discriminatory performance in this preliminary dataset. These findings support the feasibility of the EuNP-LFA as a proof-of-concept platform for rapid HSV-2 serological testing and support further evaluation in larger, clinically representative specimen populations to establish its diagnostic performance and potential utility for point-of-care applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.